Please login to the form below

Not currently logged in
Email:
Password:

SMC accepts stem cell mobilization therapy

The Scottish Medicines Consortium has accepted Mozobil for use in NHS Scotland to improve the treatment of blood cancer patients

The Scottish Medicines Consortium's (SMC) decision to accept Mozobil (plerixafor) for use in NHS Scotland has been welcomed by its developers, Genzyme UK. Mozobil is a new stem cell mobilisation therapy aimed at improving results for patients undergoing stem cell transplantation as part of their treatment for the blood cancers, multiple myeloma and lymphoma.

Mozobil is designed to help move stem cells from the bone marrow into the bloodstream and offers hope for patients who might otherwise not be able to generate sufficient stem cells for a successful transplant. Mozobil has been shown to rapidly increase the number of stem cells circulating in the blood.

Eric Low, chief executive of Myeloma UK, said: "Today's decision is very good news for Scottish patients for whom transplantation represents the most effective upfront treatment option. The fact that Mozobil increases the likelihood of collecting enough cells for a transplant is a great breakthrough for the small group of patients who cannot otherwise mobilise enough stem cells. We are delighted the Scottish Medicines Consortium has approved it for use within the NHS in Scotland."

In 2009, Mozobil received marketing authorisation from the European Medicines Agency (EMA) for use in combination with granulocyte-colony stimulating factor to enhance mobilisation of haemopoietic stem cells to the peripheral blood for collection and subsequent transplantation in patients with lymphoma and multiple myeloma whose cells mobilised poorly.

It has already been used in a number of UK hospitals on a named patient basis, for those who had failed to mobilise sufficient stem cells for transplantation using standard treatments.


 

20th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics